Yunosuke Matsuura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yunosuke Matsuura has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Koichi Kaikita
21 shared publicationsKohei Moribayashi
Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
12 shared publicationsHiroki Tanaka
Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
11 shared publications- Soichi Komaki
Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine University of Miyazaki Miyazaki Japan
8 shared publications Takeshi Ideguchi
Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
7 shared publicationsMichikazu Nakai
Department of Statistics and Data Management, Faculty of Medicine, University of Miyazaki , Miyazaki
6 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (46)
Subintimal Transcatheter Withdrawal for Active Decompression of Stent-Induced Coronary Intramural Hematoma Under Intravascular Ultrasound Guidance
- 30 September 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (46)
Open AccessSubintimal Transcatheter Withdrawal for Active Decompression of Stent-Induced Coronary Intramural Hematoma Under Intravascular Ultrasound Guidance
- Open Access
- 15 September 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
Linking Coronary Microvascular Dysfunction to Cardiac Troponin Elevation in Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is frequently accompanied by persistent elevation of high-sensitivity cardiac troponin T (hs-cTnT) and coronary microvascular dysfunction (CMD), yet their pathophysiological link remains incompletely defined. Aims: To identify the structural and functional correlates of hs-cTnT elevation in ATTR-CM. Methods and Results: We retrospectively studied 71 hospitalized patients with left ventricular hypertrophy (LVH) who underwent invasive physiological assessment of the left anterior descending artery, right heart catheterization, and endomyocardial biopsy as part of the etiological evaluation. ATTR-CM was histologically confirmed in 51 patients; the remaining 20 patients, who had no cardiac amyloidosis and alternative causes of LVH, served as a contextual reference group. The primary interpretation therefore focused on within-ATTR-CM associations. Coronary flow reserve (CFR), index of microcirculatory resistance (IMR), myocardial capillary density (MCD), and sampled transthyretin deposition were quantified and analysed in relation to hs-cTnT and haemodynamic and imaging parameters. Within the ATTR-CM cohort, higher hs-cTnT levels were independently associated with higher pulmonary artery wedge pressure (standardized β = 0.46, p = 0.0001), lower CFR (β = −0.26, p = 0.027), and lower MCD (β = −0.24, p = 0.037), but not with IMR or sampled histological transthyretin burden. Conclusions: In this selected invasive cohort with histologically confirmed ATTR-CM, higher hs-cTnT levels were independently associated with lower biopsy-derived MCD, impaired perfusion reserve, and elevated filling pressure, suggesting an integrated microvascular–haemodynamic substrate of persistent myocardial injury.
- 15 September 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
Open AccessLinking Coronary Microvascular Dysfunction to Cardiac Troponin Elevation in Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is frequently accompanied by persistent elevation of high-sensitivity cardiac troponin T (hs-cTnT) and coronary microvascular dysfunction (CMD), yet their pathophysiological link remains incompletely defined. Aims: To identify the structural and functional correlates of hs-cTnT elevation in ATTR-CM. Methods and Results: We retrospectively studied 71 hospitalized patients with left ventricular hypertrophy (LVH) who underwent invasive physiological assessment of the left anterior descending artery, right heart catheterization, and endomyocardial biopsy as part of the etiological evaluation. ATTR-CM was histologically confirmed in 51 patients; the remaining 20 patients, who had no cardiac amyloidosis and alternative causes of LVH, served as a contextual reference group. The primary interpretation therefore focused on within-ATTR-CM associations. Coronary flow reserve (CFR), index of microcirculatory resistance (IMR), myocardial capillary density (MCD), and sampled transthyretin deposition were quantified and analysed in relation to hs-cTnT and haemodynamic and imaging parameters. Within the ATTR-CM cohort, higher hs-cTnT levels were independently associated with higher pulmonary artery wedge pressure (standardized β = 0.46, p = 0.0001), lower CFR (β = −0.26, p = 0.027), and lower MCD (β = −0.24, p = 0.037), but not with IMR or sampled histological transthyretin burden. Conclusions: In this selected invasive cohort with histologically confirmed ATTR-CM, higher hs-cTnT levels were independently associated with lower biopsy-derived MCD, impaired perfusion reserve, and elevated filling pressure, suggesting an integrated microvascular–haemodynamic substrate of persistent myocardial injury.
- Open Access
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Determinants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Open AccessDeterminants and Clinical Interpretation of Circulating Transthyretin in ATTR Amyloidosis
- Open Access
- 8 August 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (41)
Severe Functional Tricuspid Regurgitation Masked by Annular Deformation in Primary Cardiac Lymphoma
- 8 August 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (41)
Open AccessSevere Functional Tricuspid Regurgitation Masked by Annular Deformation in Primary Cardiac Lymphoma
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e042486
Right Atrial Function as a Novel Predictor for New‐Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Background: Left atrial functional parameters are established predictors of atrial fibrillation (AF), but the role of right atrial (RA) function, particularly RA peak longitudinal strain (LS), in transthyretin amyloid cardiomyopathy (ATTR‐CM) remains unclear. This study aimed to investigate the relationship between RA function and AF onset in ATTR‐CM. Methods: The derivation cohort comprised 143 patients with ATTR‐CM without prior atrial arrhythmias at Kumamoto University Hospital. Association between baseline parameters and new‐onset AF during the follow‐up period was analyzed using Cox regression models. Discrimination was assessed using time‐dependent receiver operating characteristic analysis at 24 months. Results: During follow‐up (median, 30 months), 42 patients (29%) developed new‐onset AF. Lower RA peak LS was independently associated with incident AF and showed moderate discrimination (time‐dependent area under the curve, 0.72); the optimal cutoff at 24 months was 17.2%. Patients with RA peak LS <17.2% had significantly lower AF‐free survival. A novel risk score integrating RA and left atrial peak LS and LA volume index effectively stratified AF risk. External validation in an independent cohort of 81 patients from Oita and Miyazaki University Hospitals confirmed consistent associations between lower RA peak LS and higher AF incidence, supporting the reproducibility of the findings. Conclusions: RA peak LS is a novel, robust predictor of new‐onset AF in ATTR‐CM and provides additional information alongside established clinical and left atrial parameters. Incorporating RA functional assessment may improve risk stratification and guide early interventions in high‐risk patients.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e042486
Open AccessRight Atrial Function as a Novel Predictor for New‐Onset Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
Background: Left atrial functional parameters are established predictors of atrial fibrillation (AF), but the role of right atrial (RA) function, particularly RA peak longitudinal strain (LS), in transthyretin amyloid cardiomyopathy (ATTR‐CM) remains unclear. This study aimed to investigate the relationship between RA function and AF onset in ATTR‐CM. Methods: The derivation cohort comprised 143 patients with ATTR‐CM without prior atrial arrhythmias at Kumamoto University Hospital. Association between baseline parameters and new‐onset AF during the follow‐up period was analyzed using Cox regression models. Discrimination was assessed using time‐dependent receiver operating characteristic analysis at 24 months. Results: During follow‐up (median, 30 months), 42 patients (29%) developed new‐onset AF. Lower RA peak LS was independently associated with incident AF and showed moderate discrimination (time‐dependent area under the curve, 0.72); the optimal cutoff at 24 months was 17.2%. Patients with RA peak LS <17.2% had significantly lower AF‐free survival. A novel risk score integrating RA and left atrial peak LS and LA volume index effectively stratified AF risk. External validation in an independent cohort of 81 patients from Oita and Miyazaki University Hospitals confirmed consistent associations between lower RA peak LS and higher AF incidence, supporting the reproducibility of the findings. Conclusions: RA peak LS is a novel, robust predictor of new‐onset AF in ATTR‐CM and provides additional information alongside established clinical and left atrial parameters. Incorporating RA functional assessment may improve risk stratification and guide early interventions in high‐risk patients.
- Open Access
- 16 April 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
Reference Intervals and Clinical Determinants of Blood Thrombogenicity in Antithrombotic Drug-Naïve Adults Using an Advanced Microchip-Based Device
Background: The Total Thrombus-formation Analysis System 01 (T-TAS 01) is an advanced microchip-based device that enables quantitative assessment of blood thrombogenicity. However, broader clinical implementation remains limited by the lack of well-established reference intervals (RIs) in healthy, antithrombotic drug-naïve individuals. This study aimed to define RIs and identify clinical determinants of blood thrombogenicity in antithrombotic drug-naïve adults using T-TAS 01. Methods: Blood thrombogenicity was measured using T-TAS 01 in 319 adults without antithrombotic therapy who underwent health checkups at the Miyakonojo Health Service Center. The T-TAS 01 parameters, PL18-AUC10 and AR10-AUC30, were calculated as the areas under the flow–pressure curves of the PL-chip (type I collagen-coated) and the AR-chip (type I collagen and tissue factor-coated), respectively. Their associations with clinical parameters were assessed using multivariate regression analysis. Results: The median age was 46.0 years; 64.3% of participants were female, and 82.1% had no hypertension, dyslipidemia, or diabetes. The median platelet count was 247 × 109/L. The median PL18-AUC10 and AR10-AUC30 values were 392.3 and 1335.9, with RIs of 236.3 to 468.1 and 1010.0 to 1496.2, respectively. PL18-AUC10 was independently associated with white blood cell count (coefficient, 5.15; 95% CI, 0.88–9.41) and platelet count (0.36; 95% CI, 0.25–0.47), whereas AR10-AUC30 was independently associated with body mass index (4.06; 95% CI, 0.06–8.06), platelet count (0.79; 95% CI, 0.52–1.06), and γ-glutamyl transpeptidase (−0.54; 95% CI, −0.90 to −0.18). Conclusions: Our findings provide foundational reference data for the clinical application of T-TAS 01 and support its potential as a point-of-care tool for individualized assessment of thrombogenicity.
- 16 April 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
Open AccessReference Intervals and Clinical Determinants of Blood Thrombogenicity in Antithrombotic Drug-Naïve Adults Using an Advanced Microchip-Based Device
Background: The Total Thrombus-formation Analysis System 01 (T-TAS 01) is an advanced microchip-based device that enables quantitative assessment of blood thrombogenicity. However, broader clinical implementation remains limited by the lack of well-established reference intervals (RIs) in healthy, antithrombotic drug-naïve individuals. This study aimed to define RIs and identify clinical determinants of blood thrombogenicity in antithrombotic drug-naïve adults using T-TAS 01. Methods: Blood thrombogenicity was measured using T-TAS 01 in 319 adults without antithrombotic therapy who underwent health checkups at the Miyakonojo Health Service Center. The T-TAS 01 parameters, PL18-AUC10 and AR10-AUC30, were calculated as the areas under the flow–pressure curves of the PL-chip (type I collagen-coated) and the AR-chip (type I collagen and tissue factor-coated), respectively. Their associations with clinical parameters were assessed using multivariate regression analysis. Results: The median age was 46.0 years; 64.3% of participants were female, and 82.1% had no hypertension, dyslipidemia, or diabetes. The median platelet count was 247 × 109/L. The median PL18-AUC10 and AR10-AUC30 values were 392.3 and 1335.9, with RIs of 236.3 to 468.1 and 1010.0 to 1496.2, respectively. PL18-AUC10 was independently associated with white blood cell count (coefficient, 5.15; 95% CI, 0.88–9.41) and platelet count (0.36; 95% CI, 0.25–0.47), whereas AR10-AUC30 was independently associated with body mass index (4.06; 95% CI, 0.06–8.06), platelet count (0.79; 95% CI, 0.52–1.06), and γ-glutamyl transpeptidase (−0.54; 95% CI, −0.90 to −0.18). Conclusions: Our findings provide foundational reference data for the clinical application of T-TAS 01 and support its potential as a point-of-care tool for individualized assessment of thrombogenicity.
- Open Access
- 10 March 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (3) , 453-460
Clinical Determinants and Prognostic Significance of Circulating Angiopoietin-Like Protein 3 Levels in Patients With Chronic Coronary Syndrome
Background:Although angiopoietin-like protein 3 (ANGPTL3) has emerged as a novel therapeutic target for lipid modulation, its prognostic significance in chronic coronary syndrome (CCS) remains unclear. This study aimed to evaluate the clinical determinants and prognostic value of circulating ANGPTL3 levels in patients with CCS.Methods and Results:We prospectively enrolled 264 consecutive patients with CCS (median age 74 years; 73% male) undergoing cardiac catheterization. Serum ANGPTL3 levels were measured using an enzyme-linked immunosorbent assay. The primary endpoint was major adverse cardiovascular events (MACE). Female sex, elevated C-reactive protein and B-type natriuretic peptide, low high-density lipoprotein cholesterol levels, and absence of statin use were independently associated with higher ANGPTL3 levels. During follow up, 35 patients experienced MACE. In multivariable Cox regression models, ANGPTL3 remained an independent predictor of MACE. Receiver operating characteristic analysis identified 90.7 ng/mL as the optimal cut-off value for event discrimination. Kaplan-Meier curves demonstrated significantly higher event rates among patients with ANGPTL3 >90.7 ng/mL. In patients with CCS with low-density lipoprotein cholesterol (LDL-C) <70 mg/dL, elevated ANGPTL3 levels were also associated with increased MACE risk.Conclusions:Circulating ANGPTL3 levels independently predict adverse cardiovascular outcomes in CCS, including those in patients who achieve LDL-C targets, and may help identify residual cardiovascular risk not captured by traditional lipid parameters.
- 10 March 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (3) , 453-460
Open AccessClinical Determinants and Prognostic Significance of Circulating Angiopoietin-Like Protein 3 Levels in Patients With Chronic Coronary Syndrome
Background:Although angiopoietin-like protein 3 (ANGPTL3) has emerged as a novel therapeutic target for lipid modulation, its prognostic significance in chronic coronary syndrome (CCS) remains unclear. This study aimed to evaluate the clinical determinants and prognostic value of circulating ANGPTL3 levels in patients with CCS.Methods and Results:We prospectively enrolled 264 consecutive patients with CCS (median age 74 years; 73% male) undergoing cardiac catheterization. Serum ANGPTL3 levels were measured using an enzyme-linked immunosorbent assay. The primary endpoint was major adverse cardiovascular events (MACE). Female sex, elevated C-reactive protein and B-type natriuretic peptide, low high-density lipoprotein cholesterol levels, and absence of statin use were independently associated with higher ANGPTL3 levels. During follow up, 35 patients experienced MACE. In multivariable Cox regression models, ANGPTL3 remained an independent predictor of MACE. Receiver operating characteristic analysis identified 90.7 ng/mL as the optimal cut-off value for event discrimination. Kaplan-Meier curves demonstrated significantly higher event rates among patients with ANGPTL3 >90.7 ng/mL. In patients with CCS with low-density lipoprotein cholesterol (LDL-C) <70 mg/dL, elevated ANGPTL3 levels were also associated with increased MACE risk.Conclusions:Circulating ANGPTL3 levels independently predict adverse cardiovascular outcomes in CCS, including those in patients who achieve LDL-C targets, and may help identify residual cardiovascular risk not captured by traditional lipid parameters.
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
Intravascular ultrasound-guided tip detection-antegrade dissection re-entry as a bailout technique for coronary artery dissection: a case report
Background: Coronary artery dissection during percutaneous coronary intervention (PCI) may lead to haemodynamic collapse. Intravascular ultrasound (IVUS)-guided tip detection-antegrade dissection re-entry (TD-ADR) may serve as a bailout strategy. We describe a unique case in which IVUS-guided TD-ADR successfully achieved true lumen re-entry after severe coronary artery dissection. Case summary: A 64-year-old woman who had received long-term immunosuppressive therapy for rheumatoid arthritis was admitted for unstable angina. Subsequent evaluation revealed severe multivessel disease, and the patient underwent PCI of the left anterior descending artery (LAD). During the procedure, the patient experienced cardiac arrest, likely due to worsening global myocardial ischaemia, and required venoarterial extracorporeal membrane oxygenation support. IVUS demonstrated subintimal wire tracking with true lumen collapse. IVUS-guided TD-ADR using a high-penetration chronic total occlusion wire supported by a microcatheter enabled precise re-entry into the true lumen and successful LAD revascularization. Severe left circumflex artery stenoses were also considered to perpetuate myocardial ischaemia and haemodynamic instability, necessitating rescue PCI for haemodynamic stabilization. In addition, major bleeding complications due to guidewire-induced perforation of the right subclavian artery branch were managed using stenting and coil embolization. The patient showed recovery of left ventricular function and was discharged in stable condition. During the 8-month follow-up after discharge, the patient was free of adverse events. Discussion: This case highlights the feasibility of IVUS-guided TD-ADR as a bailout technique for coronary artery dissection during complex PCI. By enabling accurate true lumen re-entry, this approach facilitates timely revascularization and contributes to haemodynamic stabilization and recovery in a life-threatening setting.
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
Open AccessIntravascular ultrasound-guided tip detection-antegrade dissection re-entry as a bailout technique for coronary artery dissection: a case report
Background: Coronary artery dissection during percutaneous coronary intervention (PCI) may lead to haemodynamic collapse. Intravascular ultrasound (IVUS)-guided tip detection-antegrade dissection re-entry (TD-ADR) may serve as a bailout strategy. We describe a unique case in which IVUS-guided TD-ADR successfully achieved true lumen re-entry after severe coronary artery dissection. Case summary: A 64-year-old woman who had received long-term immunosuppressive therapy for rheumatoid arthritis was admitted for unstable angina. Subsequent evaluation revealed severe multivessel disease, and the patient underwent PCI of the left anterior descending artery (LAD). During the procedure, the patient experienced cardiac arrest, likely due to worsening global myocardial ischaemia, and required venoarterial extracorporeal membrane oxygenation support. IVUS demonstrated subintimal wire tracking with true lumen collapse. IVUS-guided TD-ADR using a high-penetration chronic total occlusion wire supported by a microcatheter enabled precise re-entry into the true lumen and successful LAD revascularization. Severe left circumflex artery stenoses were also considered to perpetuate myocardial ischaemia and haemodynamic instability, necessitating rescue PCI for haemodynamic stabilization. In addition, major bleeding complications due to guidewire-induced perforation of the right subclavian artery branch were managed using stenting and coil embolization. The patient showed recovery of left ventricular function and was discharged in stable condition. During the 8-month follow-up after discharge, the patient was free of adverse events. Discussion: This case highlights the feasibility of IVUS-guided TD-ADR as a bailout technique for coronary artery dissection during complex PCI. By enabling accurate true lumen re-entry, this approach facilitates timely revascularization and contributes to haemodynamic stabilization and recovery in a life-threatening setting.
- Open Access
- 16 February 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (2)
Basal inferoseptal longitudinal strain deformation may indicate early cardiac involvement in wild-type carpal ATTR
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is now increasingly identified as a cause of heart failure in older adults. This study aimed to clarify the morphological and functional alterations of the left ventricle (LV) that define the early stage of this condition. We prospectively evaluated 81 patients diagnosed with wild-type ATTR (ATTRwt) amyloidosis (mean age 77 ± 6 years; 88% male), categorized into three groups based on myocardial uptake on radioactive pyrophosphate scintigraphy and histological confirmation: (i) carpal ATTR without cardiac involvement (Group 1, n = 13), (ii) asymptomatic cardiac involvement (Group 2, n = 10) and (iii) overt heart failure (Group 3, n = 58). Results Compared with Group 3, Group 1 showed higher absolute global longitudinal strain (GLS) (median 19.0 [13.2–23.8]%, P < 0.001), a lower apical-sparing ratio (median 0.66 [0.55–1.04], P < 0.001) and lower brain natriuretic peptide (BNP) (median 13.5 [6–49] pg/mL, P < 0.001) and troponin-T concentrations (0.012 [0.006–0.022] ng/mL, P < 0.001), while the estimated glomerular filtration rate remained preserved (64 ± 9 mL/mL/1.73 m², P = 0.022). Segmental longitudinal strain (LS) differentiated Group 1 from Group 2, with basal inferoseptal LS significantly lower in patients with elevated troponin-T (> 0.014 ng/mL) than in those with lower values (13.9 ± 5.6 % vs. 7.4 ± 1.8 %, P = 0.046) in Group 1. A basal inferoseptal LS cutoff of 9.1% identified high troponin-T with an area under the curve (AUC) of 0.833 (P = 0.005), outperforming GLS (AUC 0.306, P = 0.217), BNP (AUC 0.667, P = 0.292) and LV ejection fraction (AUC 0.556, P = 0.743). Basal inferoseptal LS impairment may indicate early cardiac involvement in individuals with carpal tunnel syndrome carrying ATTRwt deposits.
- 16 February 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (2)
Open AccessBasal inferoseptal longitudinal strain deformation may indicate early cardiac involvement in wild-type carpal ATTR
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is now increasingly identified as a cause of heart failure in older adults. This study aimed to clarify the morphological and functional alterations of the left ventricle (LV) that define the early stage of this condition. We prospectively evaluated 81 patients diagnosed with wild-type ATTR (ATTRwt) amyloidosis (mean age 77 ± 6 years; 88% male), categorized into three groups based on myocardial uptake on radioactive pyrophosphate scintigraphy and histological confirmation: (i) carpal ATTR without cardiac involvement (Group 1, n = 13), (ii) asymptomatic cardiac involvement (Group 2, n = 10) and (iii) overt heart failure (Group 3, n = 58). Results Compared with Group 3, Group 1 showed higher absolute global longitudinal strain (GLS) (median 19.0 [13.2–23.8]%, P < 0.001), a lower apical-sparing ratio (median 0.66 [0.55–1.04], P < 0.001) and lower brain natriuretic peptide (BNP) (median 13.5 [6–49] pg/mL, P < 0.001) and troponin-T concentrations (0.012 [0.006–0.022] ng/mL, P < 0.001), while the estimated glomerular filtration rate remained preserved (64 ± 9 mL/mL/1.73 m², P = 0.022). Segmental longitudinal strain (LS) differentiated Group 1 from Group 2, with basal inferoseptal LS significantly lower in patients with elevated troponin-T (> 0.014 ng/mL) than in those with lower values (13.9 ± 5.6 % vs. 7.4 ± 1.8 %, P = 0.046) in Group 1. A basal inferoseptal LS cutoff of 9.1% identified high troponin-T with an area under the curve (AUC) of 0.833 (P = 0.005), outperforming GLS (AUC 0.306, P = 0.217), BNP (AUC 0.667, P = 0.292) and LV ejection fraction (AUC 0.556, P = 0.743). Basal inferoseptal LS impairment may indicate early cardiac involvement in individuals with carpal tunnel syndrome carrying ATTRwt deposits.
- Open Access
- 15 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (5) , e70250
Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
Aims: To evaluate the impact of diabetes on in‐hospital outcomes among patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) who were hospitalized for cardiovascular disease (CVD). Methods: We conducted a retrospective cross‐sectional study using data from the nationwide Japanese Registry of All Cardiac and Vascular Diseases‐Diagnosis Procedure Combination, from April 2012 to March 2023. A total of 10,614 patients with MASLD hospitalized for CVD were identified, of whom 4550 (42.9%) had diabetes. The primary outcome was in‐hospital mortality, and secondary outcomes were major cardiac and non‐cardiac complications. Results: The median age was 66 years, and 66.9% were male. Compared with patients without diabetes, those with diabetes had higher rates of ischaemic heart disease (35.5% vs. 30.8%), acute coronary syndrome (18.8% vs. 16.9%) and heart failure (27.3% vs. 25.4%) (all p < 0.05). In‐hospital mortality (5.6% vs. 3.3%; p < 0.001) and overall complication rates (23.6% vs. 19.7%; p < 0.001) were significantly greater in the diabetes group, driven mainly by cardiac events (16.8% vs. 10.5%; p < 0.001). Multivariable logistic regression confirmed diabetes as an independent predictor of in‐hospital mortality (odds ratio, 1.99; 95% confidence interval, 1.60–2.47; p < 0.001). Conclusions: Diabetes was associated with higher in‐hospital mortality and complication rates among patients with MASLD hospitalized for CVD. Stratification of MASLD by metabolic phenotype, particularly in the presence of diabetes, may help improve risk assessment and inform more personalized clinical management in this population.
- 15 February 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (5) , e70250
Open AccessAssociation between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study
Aims: To evaluate the impact of diabetes on in‐hospital outcomes among patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) who were hospitalized for cardiovascular disease (CVD). Methods: We conducted a retrospective cross‐sectional study using data from the nationwide Japanese Registry of All Cardiac and Vascular Diseases‐Diagnosis Procedure Combination, from April 2012 to March 2023. A total of 10,614 patients with MASLD hospitalized for CVD were identified, of whom 4550 (42.9%) had diabetes. The primary outcome was in‐hospital mortality, and secondary outcomes were major cardiac and non‐cardiac complications. Results: The median age was 66 years, and 66.9% were male. Compared with patients without diabetes, those with diabetes had higher rates of ischaemic heart disease (35.5% vs. 30.8%), acute coronary syndrome (18.8% vs. 16.9%) and heart failure (27.3% vs. 25.4%) (all p < 0.05). In‐hospital mortality (5.6% vs. 3.3%; p < 0.001) and overall complication rates (23.6% vs. 19.7%; p < 0.001) were significantly greater in the diabetes group, driven mainly by cardiac events (16.8% vs. 10.5%; p < 0.001). Multivariable logistic regression confirmed diabetes as an independent predictor of in‐hospital mortality (odds ratio, 1.99; 95% confidence interval, 1.60–2.47; p < 0.001). Conclusions: Diabetes was associated with higher in‐hospital mortality and complication rates among patients with MASLD hospitalized for CVD. Stratification of MASLD by metabolic phenotype, particularly in the presence of diabetes, may help improve risk assessment and inform more personalized clinical management in this population.